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Abstract 
Histamine is a transmitter that activates the four receptors H1R to H4R. The H3R is 
found in the nervous system as an auto and heteroreceptor, and controls the release 
of neurotransmitters, making it a potential drug target for neuropsychiatric conditions. 
We have previously reported that the 1-(2,3-dihydro-1-benzofuran-2-
yl)methylpiperazines (LINS01 compounds) have selectivity for the H3R over the H4R. 
Here we describe their pharmacological properties at the human H1R, H2R in parallel 
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with the H3R, thus providing a full analysis of these compounds as histamine 
receptor ligands through reporter gene assays. Eight of the nine LINS01 compounds 
inhibited H3R-induced histamine responses but no inhibition of H2R-induced 
responses were seen. Three compounds were weakly able to inhibit H1R-induced 
responses. No agonist responses were seen to any of the compounds at any 
receptor. SAR analysis shows that the N-methyl group improves H3R affinity whilst 
the N-phenyl group is detrimental. The methoxy derivative, LINS01009, had the 
highest affinity. 
 
Histamine is a biogenic amine that has important clinical and pathophysiological 
roles in allergy, gastric acid secretion and inflammatory diseases. Histamine effects 
occur by activation of histamine receptors of which there are four subtypes and all 
are G-protein coupled receptors (GPCRs), namely H1R, H2R, H3R and H4R.
[1,2] 
 
The H1R is a Gq-coupled receptor and activation of this is important in allergy. There 
are many H1R-antagonists in widespread clinical use for allergies such as hayfever 
(including oral agents e.g. certirizine, loratadine and chlorpheniramine, and topical 
preparations e.g. mepyramine). The H2R is a Gs-coupled receptor. Activation is 
important in the production of gastric acid and H2R-antagonists are widely used to 
reduce gastric acid production (e.g. ranitidine).[1] The H3R is a Gi-coupled receptor 
and present in the CNS and on peripheral neurons. It is important for inhibiting the 
release of histamine (as an autoreceptor) but also negatively regulating the synthesis 
and release of many neurotransmitters. H3R-antagonists have been investigated as 
potential treatments for several CNS disorders, including sleep disorders, 
schizophrenia, epilepsy, attention deficit and hyperactivity disorder and even obesity. 
There is also potential for H3R-antagonists to have effects in neurodegenerative 
disorders such as Alzheimer’s, Parkinson’s disease and  Huntington’s chorea.[3-6] 
Recently, a H3R antagonist (pitolisant) has been approval for the maintenance of 
wakefulness in patients with narcolepsy.[7,8] The H4R is also a Gi-coupled receptor 
and is most widely expressed in bone marrow and on white blood cells and shown to 
be an important target to treat inflammation,[2] although to date no H4R antagonist is 
available for clinical use. There is a considerable overlap between the selectivity of 
ligands for the H3R and H4R, with many H3R ligands having high affinity for the H4R, 
however some H4R selective ligands have been identified (e.g. JNJ-7777120).
[1,2] We 
have recently developed a series of compounds, originally designed based on the 
H4R selective antagonist JNJ-7777120 chemophore, the 1-(2,3-dihydro-1-
benzofuran-2-yl)methylpiperazines (LINS01) series (Figure 1). 
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Initial studies examining [3H]-histamine binding to H3R and H4R membrane 
preparations of the first four compounds suggested micromolar affinities for these 
compounds, with higher affinity for the H3R than H4R.
[9]  A further study of other 
LINS01 compounds in HEK293 cells transiently expressing the H3R or H4R 
suggested the LINS01 compounds are antagonists or weak inverse agonists but 
once again that they had higher affinity for the H3R than the H4R.
[10] Given the 
surprising finding that these LINS01 compounds had higher affinity for H3R than H4R, 
we decided to investigate the pharmacological profile of these ligands at the other 
histamine receptors, the H1R and H2R. 
 
The LINS01 compounds (1a-1i) were synthesized as previously reported by our 
group (Figure 2, see supporting Information).[9-11] In case of the non-substituted 
phenols (to obtain compounds 1a-d), the commercial 2-allylphenol was used as 
starting material. In case of R’-substituted molecules, the corresponding phenols 2e-
h were used as starting material, which were allylated with allyl bromide in 
conventional or ultrasonic conditions, with good to excellent yields. The yields in 
conventional or ultrasonic methods are comparable, however the ultrasonic 
methodology saved reaction time and thus was considered advantageous. The allyl-
phenyl ethers 3e-h were then thermally isomerized (>200 °C) to access the 2-
allylphenols (4a-h) with good yield using a microwave-assisted Claisen 
rearrangement approach, using DMF as solvent. The dihydrobenzofurans (5a-h) 
were obtained through iodine-promoted cyclization from the corresponding ortho-
allylphenols in an eco-friendly medium, using water or a mixture of ethanol-water as 
solvent. Finally, the iodinated heterocycle was used to alkylate the N-substituted 
piperazines in aprotic solvent (THF), with potassium carbonate as base, with 
moderate yields. A novel microwave-assisted methodology was employed to avoid 
the considerable excess of 1-phenylpiperazine to obtain compounds 1d and 1i, 
leading to moderate to good yields (50-70%). Although this method gave comparable 
yields to the conventional methodology, it also saved reaction time and required less 
1-phenylpiperazine (1.1 eq.) indeed, then comprising the green chemistry 
principles.[12] The spectroscopic data for the final compounds (see Supporting 
Information) and intermediates are in accordance to the literature reports.[9-11] None 
of the LINS01 molecules were previously evaluated in H1R and H2R, and the 
compound 1i was not evaluated in H3R before. This is also the first report on the 
affinity data for these compounds through reporter gene assays. 
 
Histamine stimulated a response that was 2.3 ± 0.1 fold over basal in the H1-SRE-
luciferase cells (pEC50 6.78 ± 0.04; n=8, Figure 3a,b). This response was readily 
inhibited by mepyramine, a histamine H1R antagonist, causing a parallel rightward 
shift of the histamine concentration response and yielding a pKD value of 8.53 ± 0.05 
(n=9). ICI162846 (an H2R antagonist) and JNJ-7777120 (an H4R antagonist) were 
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not able to antagonize the histamine response at concentrations of up to 10 µM. 
Clobenproprit (an H3R/H4R antagonist) caused a small rightward shift of the 
histamine response (pKD 5.01 ± 0.11; n=9).  Thus histamine responses are readily 
antagonized by mepyramine, but not ICI182846, clobenpropit or JNJ-7777120, 
confirming the presence of the H1R in this cell line.
[13] 
 
Histamine also stimulated a response (pEC50 7.50 ± 0.03; n=8) in the H2-CRE-SPAP 
cells that was 3.8 ± 0.1 fold over basal (Figure 3c,d). This response was inhibited by 
the H2R antagonist ICI162846 (pKD 8.71 ± 0.04; n=9) whereas neither mepyramine 
nor clobenpropit nor JNJ-7777120 were able to cause a rightward shift of the 
histamine concentration response curve.  This confirms the presence of the H2R in 
this cell line.[13]  
 
Histamine did not stimulate a response, nor inhibit the basal response, on its own in 
the CHO-H3-CRE-SPAP cells, indicating the absence of a Gs-coupled stimulatory 
histamine receptor.[14] Histamine did however inhibit forskolin-induced CRE-SPAP 
production (pEC50 6.66 ± 0.04; n=9) in a manner consistent with stimulation of a Gi-
coupled histamine receptor (Figure 3e,f). This histamine Gi-induced agonist 
response was inhibited by clobenproprit (pKD 9.18 ± 0.06; n=9). As expected, neither 
mepyramine nor ICI162846 were able to inhibit the histamine responses in this cell 
line. JNJ-7777120 cause a small rightward shift of the histamine-concentration 
response curve (pKD 5.45 ± 0.07; n=4), very similar to that previously reported for the 
human H3R (pKD 5.29) and very different from that for the histamine H4R (pKD 
8.40).[15] Thus the presence of the histamine H3R was confirmed in this cell line.
[14] 
 
None of the LINS01 compound series stimulated any agonist responses in any of the 
cell lines (Figure 4).  With the exception of 1a, the LINS01 compounds were able to 
inhibit the H3R histamine induced response to yield measureable pKD values. The 
compound 1g had the highest affinity (pKD 7.18) followed by 1h (pKD 6.99; Figure 4, 
Table 1). Increasing concentrations of 1g caused progressive rightward shifts of the 
histamine concentration response curve in keeping with competitive antagonism at 
the H3R (Figure 4e). Three compounds did cause a small rightward shift of the 
histamine response in CHO-H1-SRE-luciferase cells giving measureable pKD values. 
Interestingly, 1a, that did not have any measureable affinity for the H3R, had a very 
weak affinity for the H1R.  None of the LINS01 ligands had any measureable affinity 
for the H2R. 
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As the LINS01 molecules were originally designed to be similar to the H4R selective 
antagonist JNJ-7777120,[9] it was expected that these molecules would also be H4-
selective. Indeed, two molecules (LINS01005 – 1d and LINS01007 – 1e) appear to 
have a dose-dependent anti-inflammatory effect in a murine mouse model of asthma 
that correlated with the H4R affinity.
[9,10] However, these studies have also shown 
that most of LINS01 molecules actually have higher affinity for the H3R than the 
H4R.
[9,10] It was therefore important to know the pharmacological profile of these 
compounds for the human H1R and H2R.  
 
The LINS01 compounds, together with mepyramine (selective H1R antagonist), ICI 
162864 (selective H2R antagonist), clobenpropit (H3R/H4R antagonist) and JNJ-
7777120 (H4R antagonist) were studied using the functional read out of reporter 
gene assays in CHO cell lines stable expressing each of the human H1R, H2R and 
H3R. For the Gq-coupled H1R, an SRE-reporter was used, whereas for the Gs-
coupled H2R and Gi-coupled H3R (both of which affect cAMP) a CRE-reporter was 
used.[13,14] Reporter gene assays have several advantages. They can be used to 
examine responses from receptors without the need for large extracellular or 
intracellular tags, which have the potential to alter the ligand-receptor binding or 
receptor-effector coupling respectively. The longer agonist incubation times (here, 5 
h at 37 °C) means that the interaction between the ligand and the receptor is highly 
likely to reach equilibrium allowing the use of pharmacological analyses such as the 
rightward shift of agonist concentration responses (Gaddum equation)[13,14] to assess 
ligand affinity (often not possible with very short term second messenger responses 
such as calcium). Thus the efficacy of ligands (ability to stimulate a response) and 
the affinity of antagonist ligands can be assessed within one assay. Also unlike 
second messenger assays (e.g. calcium, cAMP), being downstream responses, 
reporter gene assays also read out from several different signaling cascades (e.g. 
cAMP and MAP kinase).[16] 
 
None of the LINS01 compounds stimulated any agonist responses at any of the 
histamine receptors studied. Although each of the selective antagonists inhibited 
histamine responses with high affinity at their respective receptors, no inhibition of 
histamine responses were seen with the LINS01 compounds in the H2R expressing 
cells. There is therefore no evidence for any ligand-receptor interaction for the 
LINS01 compounds with the H2R. Three of the LINS compounds had a measureable 
affinity, albeit low, for the human H1R. Of these, 1a is most interesting in that this 
compound was the one compound from the LINS01 series that had no affinity for the 
H3R. The compound 1a therefore appears to have H1R selectivity (although the H1R 
affinity is very poor). All compounds with the exception of 1a antagonized histamine 
responses yielding measurable pKD values. 
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Looking into the SAR on the H3R affinity, the importance of the N-alkyl group (R) is 
clear. The unsubstituted compound (1a) had no affinity for the H3R although did for 
the H1R. Substitution with either N-methyl (1b) or N-allyl (1c) groups led to improved 
H3R affinity, suggesting there is an additional hydrophobic interaction of the R-group 
in the binding site. The N-phenyl group (1d) also decreased H3R affinity, possibly 
due steric hindrance or by decreasing the basicity of the nitrogen. Thus the N-alkyl 
group is important for H3R affinity, and possible lack of it important for H1R affinity. 
 
Several H3R ligands reported in the literature present the N-arylpiperazine moiety 
such as DL-80[17] which present medium to low affinity to H3R, but with certain 
selectivity over H4R. However these compounds present a longer linker than the 
LINS01 compounds, and thus the position of the most basic nitrogen changes 
accordingly. Docking studies[18,19] suggest that a salt bridge between a basic nitrogen 
and Glu206 is a key interaction to the antagonist activity. Figure 5 shows the 
proposed interactions of several antagonists with H3R, and the hypothetical 
interaction of 1g. The alignment of UCL2190, DL-80 and 1g (Figure 5) suggests that 
the nitrogens supposed to interact with Glu206 and the aromatic rings of these 
molecules can occupy the same positions in space, supporting this hypothesis. 
 
We have previously shown that only compounds 1e and 1f showed any measureable 
affinity for the H4R, suggesting that the R’ group may play the role in the H4R affinity. 
Compound 1e also presented similar pKi for both receptors (~6.0).
[10] The high 
homology between these two receptors explains the non-selectivity of several 
ligands from literature. It is known that H3R and H4R share two highly conserved 
amino acids in the binding site, an aspartate (Asp114 and Asp94, respectively) and 
an glutamate (Glu206 and Glu182, respectively), which interact with the primary 
amine and imidazole, respectively, of histamine. This explains the higher affinity of 
histamine for these receptors than for H1R and H2R.
[20] The interaction with Glu206 
generally determines the affinity of H3R ligands and possibly the low affinity of these 
ligands to H1R and H2R, since Glu206 is not present in these receptors. By 
observing the present results, we believe that the more basic nitrogen of LINS01 
compounds interact with Glu206 by analogy. 
The results also suggest that some volume in the R’ region is tolerated by H3R. As 
can be noted in Table 1, compounds 1e-1h present a substituent in R’ and the 
binding affinities kept similar. The presence of the bulky t-butyl group in 1h 
maintained the binding affinity value ~7.0, corroborating this hypothesis. However, 
the more polar methoxy group led to better affinity (pKD 7.18), suggesting that polar 
atoms can improve the potency without increasing lipophilicity indeed. Molecules 
with excessive lipophilicity can lead to pharmacokinetic issues in the development 
stage, and thus should be avoided at initial stages.[21] 
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Ligand efficiency metric analysis (see Supporting Information) is a suitable approach 
to evaluate the contribution of each atom of a given molecule to the binding 
affinity.[21,22] The concept of ligand efficiency (LE) arouse from the need to measure 
whether a potency of a ligand derives from an adequate fit with the target or simply 
by doing many nonspecific interactions with it.[23] Literature considers that a good LE 
value to a lead-like molecule is at least >0.3, while market drugs present an average 
LE value >0.45.[21,22] All LINS01 compounds presented LE >0.3 regarding H3R 
affinity, and thus can be considered promising compounds for further development. 
Compounds 1b, 1f and 1g must be highlighted due to their high LE values (>0.52), 
and with exception of the N-phenyl derivatives 1d and 1i, the LINS01 molecules 
present LE values comparable to drugs that are doing well in the market. The fit 
quality (FQ) is a size-independent measurement of LE, i.e. it allows direct 
comparison of the values independently from the molecular size.[24] Again, the 
LINS01 compounds present very good values for FQ and are considered interesting 
lead compounds. 
 
Derivations of LE concept considering the lipophilicity also appeared, such as the 
lipophilicity-corrected ligand efficiency (LELP) and the lipophilic ligand efficiency 
(LLE), in order to ponder the LE with the lipophilicity (mainly measured by clogP, see 
Supporting Information).[25,26] Excessive hydrophobicity should be avoided during 
drug discovery process because it limits the water solubility (which directly impacts 
on pharmacokinetics) and favors nonspecific interactions with biological proteins. 
The optimum LELP values are considered in the range from -10 to +10, while LLE 
values should be between 5 and 7.[21] Once again, the N-phenyl derivatives 1d and 
1i showed LELP values outside the desired values, indicating that the phenyl group 
led to excessive lipophilicity. This lipophilicity can be verified by the high clogP 
values for these molecules. Considering that the lipophilicity usually increases during 
the development,[25] these molecules are not promising for further modifications, or 
these modifications should consider more hydrophilic groups. The LLE value of 1g is 
within the optimal value, indicating that the insertion of methoxy group in R’ led to 
improved affinity and contributed to reduce the lipophilicity of the molecule at the 
same time, leading to a clogP value similar to that from the non-substituted molecule 
1b.   
 
Group efficiency (GE) is also a metric value to evaluate the contribution of an 
inserted group to the potency.[27] LINS01 molecules present a common 
dihydrobenzofuranyl-methylpiperazine core with structural modifications in the basic 
nitrogen (R) and in the aromatic ring (R’). As can be noted in Tables 1 and 2, 
modifications in the R-group lead to important variations in the binding affinities. The 
presence of N-methyl group led to important improvement in the affinity to H3R (GE = 
2.29), indicating that this group should be maintained to good H3R affinity. The N-
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allyl group also increased the affinity, but as it present 3 heavy atoms its efficiency 
was lower than N-methyl (GE = 0.85). In counterpart the N-phenyl group of 1d 
presented low GE value. The higher the GE value, the higher the contribution of the 
group to increase the potency. For example, the addition of a group with one heavy 
atom (HA = 1) and a GE value of 0.52 in a molecule with molecular weight <300 
means an increase of 2.3-fold in potency.[21,27] This means that the N-methyl group 
contributes very importantly to the binding affinity, while the N-phenyl group neither 
and thus its insertion in the molecule do not justify. The contribution of the R’ group 
in the potency, as indicated by GE values, is less prominent. In the case of chlorine 
atom in 1e, negative GE value was observed, stating the negative contribution of this 
atom to the affinity. The best contribution was given by the methoxy group of 1g (GE 
= 0.35). 
 
In summary, the dihydrobenzofuranyl-methylpiperazine (LINS01) molecules are 
selective H3R antagonists with no intrinsic activity at either the human histamine 
H1R, H2R or H3R and no, or extremely poor, affinity for the H1R or H2R. Although the 
best ligands (1g and 1h) have greater than 100-fold H3R selectivity (over H1R or 
H2R), their affinities for the human H3R (66 nM and 100 nM) clearly show potential 
scope for further improvement with different chemical modifications. As future 
directions, this chemical scaffold should be used to design novel derivatives in order 
to increase the affinity to H3R taking advantage on the selectivity profile of such 
compounds. 
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Figure Captions 
 
Figure 1. Structure of LINS01 compounds. 
 
Figure 2. Reagents and conditions. a. Phenol, allyl bromide (2 eq.), K2CO3 (2 eq.), 
acetone, 60 ºC, ))) 4h or conventional 12 h; b. 200 ºC, MW (300 W max., 300 psi 
max.), DMF, 1 h; c. I2 (1.1 eq.), water, 4-8 h; d. Piperazines (NH, N-Me, N-allyl, N-
Ph, 2-4 eq.), K2CO3 (1 eq.), THF, 80 ºC, 24 h or 1-phenylpiperazine (1.1 eq.), MW 
(300 psi max, 300 W max), 120 ºC, 1.5 h. 
 
Figure 3. Reporter gene production in response to in the absence and presence of 
different antagonist ligands in CHO-H1-SRE-luciferase cells (a and b), CHO-H2-
CRE-SPAP cells (c and d) and CHO-H3-CRE-SPAP cells (e and f). Bars represent 
basal CRE-SPAP production, that in response to 10 µM histamine, 10 µM PDBU, 3 
µM forskolin, or antagonist alone. Data points are mean ± SEM of triplicate 
determinations. These single experiments are representative of 4 (a), 8 (b), 4 (c), 8 
(d), 4 (e) and 8 (f) separate experiments. 
 
Figure 4. Reporter gene production in response in response to different LINS01 
ligands CHO-H1-SRE-luciferase cells (a and b), CHO-H2-CRE-SPAP cells (c and d) 
and CHO-H3-CRE-SPAP cells (e and f). Bars represent basal CRE-SPAP 
production, that in response to 10 µM histamine, 10 µM PDBU or 3 µM forskolin 
alone. Data points are mean ± SEM of triplicate determinations. These single 
experiments are representative of 4 separate experiments in each case. 
 
Figure 5. Proposed interactions of H3R ligands with Glu206 (blue dashed lines). (A) 
UCL2190; (B) DL-80; (C) LINS01009 (1g); (D) Alignment of UCL2190 (yellow), DL-
80 (purple) and LINS01009 (grey) considering the aromatic ring and basic nitrogen 
involved in the interaction with Glu206. 
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Tables 
 
Table 1. pKD values for the human H1R, H2R and H3R. 
Compounds H1R pKD (n) H2R pKD (n) H3R pKD (n) 
1a 5.27 ± 0.10 (4) <5.00 (4) <5.00 (4) 
1b 5.66 ± 0.10 (4) <5.00 (4) 6.67 ± 0.07 (5) 
1c <5.00 (4) <5.00 (4) 6.87 ± 0.07 (5) 
1d <5.00 (4) <5.00 (4) 5.61 ± 0.13 (4) 
1e <5.00 (8) <5.00 (8) 6.31 ± 0.06 (8) 
1f <5.00 (4) <5.00 (4) 6.80 ± 0.10 (6) 
1g <5.00 (10) <5.00 (10) 7.18 ± 0.04 (15) 
1h <5.00 (8) <5.00 (8) 6.99 ± 0.02 (8) 
1i 5.87 ± 0.04 (8) <5.00 (8) 6.29 ± 0.03 (8) 
mepyramine 8.53 ± 0.05 (9) <5.00 (8) <5.00 (9) 
ICI162846 <5.00 (9) 8.71 ± 0.04 (9) <5.00 (9) 
clobenpropit 5.01 ± 0.11 (9) <5.00 (8) 9.18 ± 0.06 (9) 
JNJ-7777120 <5.00 (4) <5.00 (4) 5.45 ± 0.07 (4) 
pKD values for ligands as determined in reporter assays from the rightward parallel 
shift of a histamine concentration response curve. Values are mean ± SEM of n 
separate determinations. 
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Table 2. Ligand metric analyses of the LINS01 compounds considering the H3R 
affinity. 
Compounds clogP LE LELP LLE FQ GE 
1a 1.30 >0.43 <3.04 >3.70 >0.56 - 
1b 1.90 0.54 3.53 4.77 0.74 >2.29a 
1c 2.54 0.50 5.13 4.33 0.74 >0.85a 
1d 3.59 0.35 10.28 2.02 0.59 >0.14a 
1e 2.73 0.48 5.68 3.58 0.69 -0.49b 
1f 2.32 0.52 4.48 4.48 0.74 0.18b 
1g 1.93 0.52 3.73 5.25 0.78 0.35b 
1h 3.58 0.46 7.85 3.41 0.74 0.11b 
1i 4.02 0.37 10.73 2.27 0.65 0.93c 
clobenpropit 2.67 0.62 4.25 6.51 0.98 - 
aCalculated for the R-group based on 1a. 
bCalculated for the R’-group based on 1b. 
cCalculated for R’-group based on 1f.  
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